The cost-effectiveness of male HPV vaccination in the United States. (Q48617316)

13 February 2018

title

The cost-effectiveness of male HPV vaccination in the United States. (English)

1 reference

13 February 2018

cost-effectiveness analysis

main subject

United States of America

0 references

1 reference

5

Lauri E Markowitz

1 reference

13 February 2018

author name string

Harrell W Chesson

1

1 reference

13 February 2018

Donatus U Ekwueme

2

1 reference

13 February 2018

Mona Saraiya

3

1 reference

13 February 2018

Eileen F Dunne

4

1 reference

13 February 2018

language of work or name

English

0 references

publication date

2 August 2011

1 reference

13 February 2018

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

13 February 2018

volume

29

1 reference

13 February 2018

page(s)

8443-8450

1 reference

13 February 2018

issue

46

1 reference

13 February 2018

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Cost-effectiveness of a potential vaccine for human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Evaluating human papillomavirus vaccination programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Cost-effectiveness of human papillomavirus vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Health and economic implications of HPV vaccination in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Impact of vaccinating boys and men against HPV in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Economic evaluation of human papillomavirus vaccination in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Economic evaluation of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Gardasil: from bench, to bedside, to blunder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Understanding and overcoming barriers to human papillomavirus vaccine acceptance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Diagnoses and outcomes in cervical cancer screening: a population-based study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Abnormal outcomes following cervical cancer screening: event duration and health utility loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Assessing incidence and economic burden of genital warts with data from a US commercially insured population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

The economic burden of noncervical human papillomavirus disease in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.096

10.1016/J.VACCINE.2011.07.096

7 January 2021

Identifiers

DOI

1 reference

13 February 2018

PubMed ID

21816193

1 reference

13 February 2018